Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients

Read post on prnewswire.com

Positive interim findings drive early trial conclusion; Hoth prepares to seek FDA alignment on a potential pivotal study for cancer treatment–related skin toxicity HOBOKEN, N.J., Nov. 3, 2026 /PRNewswire/ -- Rocket One Inc. (Nasdaq: RKTO) ("Rocket One" or the "Company") today announced...